<VariationArchive VariationID="439772" VariationName="NM_000517.6(HBA2):c.*93_*94del" VariationType="Deletion" Accession="VCV000439772" Version="18" RecordType="classified" NumberOfSubmissions="4" NumberOfSubmitters="4" DateLastUpdated="2024-07-29" DateCreated="2017-09-30" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="433153" VariationID="439772">
      <GeneList>
        <Gene Symbol="HBA2" FullName="hemoglobin subunit alpha 2" GeneID="3040" HGNC_ID="HGNC:4824" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>16p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="172876" stop="173710" display_start="172876" display_stop="173710" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="222845" stop="223708" display_start="222845" display_stop="223708" Strand="+" />
          </Location>
          <OMIM>141850</OMIM>
        </Gene>
        <Gene Symbol="LOC106804612" FullName="hemoglobin subunit alpha 2 recombination region" GeneID="106804612" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>16p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="170362" stop="173729" display_start="170362" display_stop="173729" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000517.6(HBA2):c.*93_*94del</Name>
      <CanonicalSPDI>NC_000016.10:173691:AAA:A</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="173692" stop="173693" display_start="173692" display_stop="173693" variantLength="2" positionVCF="173691" referenceAlleleVCF="TAA" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="223691" stop="223692" display_start="223691" display_stop="223692" variantLength="2" positionVCF="223690" referenceAlleleVCF="TAA" alternateAlleleVCF="T" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.173693_173694del" Assembly="GRCh38">
            <Expression>NC_000016.10:g.173693_173694del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.223692_223693del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.223692_223693del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_000006.1" sequenceAccession="NG_000006" sequenceVersion="1" change="g.34556_34557del">
            <Expression>NG_000006.1:g.34556_34557del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_046165.1" sequenceAccession="NG_046165" sequenceVersion="1" change="g.3432_3433del">
            <Expression>NG_046165.1:g.3432_3433del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_059186.1" sequenceAccession="NG_059186" sequenceVersion="1" change="g.2043_2044del">
            <Expression>NG_059186.1:g.2043_2044del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_059271.1" sequenceAccession="NG_059271" sequenceVersion="1" change="g.5847_5848del">
            <Expression>NG_059271.1:g.5847_5848del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000517.6" sequenceAccession="NM_000517" sequenceVersion="6" change="c.*93_*94del" MANESelect="true">
            <Expression>NM_000517.6:c.*93_*94del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1225" sequenceAccession="LRG_1225">
            <Expression>LRG_1225:g.2043_2044del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1240" sequenceAccession="LRG_1240">
            <Expression>LRG_1240:g.5847_5848del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1240t1" sequenceAccession="LRG_1240t1">
            <Expression>LRG_1240t1:c.*93_*94del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000517.4" sequenceAccession="NM_000517" sequenceVersion="4" change="c.*93_*94del">
            <Expression>NM_000517.4:c.*93_*94del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000517.6" sequenceAccession="NM_000517" sequenceVersion="6" change="c.*93_*94delAA" MANESelect="true">
            <Expression>NM_000517.6:c.*93_*94delAA</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA276415710" DB="ClinGen" />
        <XRef Type="rs" ID="63751268" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000517.6(HBA2):c.*93_*94del AND not provided" Accession="RCV001284139" Version="18">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-06-22" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000517.6(HBA2):c.*93_*94del AND alpha Thalassemia" Accession="RCV001834638" Version="11">
        <ClassifiedConditionList TraitSetID="4863">
          <ClassifiedCondition DB="MedGen" ID="C0002312">alpha Thalassemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-03-17" SubmissionCount="2">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-06-22" NumberOfSubmissions="4" NumberOfSubmitters="4" DateCreated="2017-09-30" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16103716</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17054428</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17486499</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20507641</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26193977</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">7803252</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">7947237</ID>
        </Citation>
        <DescriptionHistory Dated="2022-08-04">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="4863" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6489" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Alpha thalassemia spectrum</ElementValue>
                <XRef ID="MONDO:0011399" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">A-Thalassemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">alpha Thalassemia</ElementValue>
                <XRef ID="Alpha-Thalassemia/333" DB="Genetic Alliance" />
                <XRef ID="68913001" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="621" />
                <XRef ID="621" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Alpha-thalassemia (α-thalassemia) has two clinically significant forms: hemoglobin Bart hydrops fetalis (Hb Bart) syndrome (caused by deletion/inactivation of all four α-globin genes; --/--), and hemoglobin H (HbH) disease (most frequently caused by deletion/inactivation of three α-globin genes; --/-α). Hb Bart syndrome, the more severe form, is characterized by prenatal onset of generalized edema and pleural and pericardial effusions as a result of congestive heart failure induced by severe anemia. Extramedullary erythropoiesis, marked hepatosplenomegaly, and a massive placenta are common. Death usually occurs in the neonatal period. HbH disease has a broad phenotypic spectrum: although clinical features usually develop in the first years of life, HbH disease may not present until adulthood or may be diagnosed only during routine hematologic analysis in an asymptomatic individual. The majority of individuals have enlargement of the spleen (and less commonly of the liver), mild jaundice, and sometimes thalassemia-like bone changes. Individuals with HbH disease may develop gallstones and experience acute episodes of hemolysis in response to infections or exposure to oxidant drugs.</Attribute>
                <XRef ID="NBK1435" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301608</ID>
                <ID Source="BookShelf">NBK1435</ID>
              </Citation>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FA + Barts Hb, Alpha (a) Thalassemia, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics Newborn Screening ACT sheet, FA + Barts present (unquantified), FAB, Alpha Thalassemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Unquantified Barts Alpha Thalassemia Screening Result (FAB), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Low/Moderate Barts Alpha Thalassemia Screening Result (FAB2; FAB1), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-ACT-Sheet.pdf</URL>
                <CitationText>ACMG ACT, FA + Low/Moderate Barts Hb, FAB2, FAB1 Alpha Thalassemia: Silent carrier and alpha thalassemia trait, 2023</CitationText>
              </Citation>
              <XRef ID="846" DB="Orphanet" />
              <XRef ID="C0002312" DB="MedGen" />
              <XRef ID="MONDO:0011399" DB="MONDO" />
              <XRef Type="MIM" ID="604131" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4081763" SubmissionDate="2022-02-09" DateLastUpdated="2022-02-13" DateCreated="2022-02-13">
        <ClinVarSubmissionID localKey="NM_000517.6:c.*93_*94del|Alpha thalassemia" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002093853" DateUpdated="2022-02-13" DateCreated="2022-02-13" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-01-29">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000517.6:c.*93_*94del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Alpha thalassemia</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5002441" SubmissionDate="2022-12-11" DateLastUpdated="2022-12-17" DateCreated="2022-08-08">
        <ClinVarSubmissionID localKey="sa_pathology/molecular_genetics_frome_rd/vc13758" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002556487" DateUpdated="2022-12-17" DateCreated="2022-08-08" Type="SCV" Version="2" SubmitterName="Genetics and Molecular Pathology, SA Pathology" OrgID="506043" OrganizationCategory="laboratory" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-03-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>PM2, PP5, PP1, PM1</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_1450</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000517.6:c.*93_*94delAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="604131" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_33</SubmissionName>
          <SubmissionName>submission_36</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2897070" SubmissionDate="2023-12-22" DateLastUpdated="2024-01-06" DateCreated="2021-01-26">
        <ClinVarSubmissionID localKey="S4162|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001469765" DateUpdated="2024-01-06" DateCreated="2021-01-26" Type="SCV" Version="2" SubmitterName="Quest Diagnostics Nichols Institute San Juan Capistrano" OrgID="500110" OrganizationCategory="laboratory" OrgAbbreviation="Quest Diagnostics" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-01-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">26193977</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17054428</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16103716</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17486499</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">7803252</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20507641</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">7947237</ID>
          </Citation>
          <Comment>The HBA2 c.*93_*94delAA pathogenic variant is located in the 3'-untranslated region of the HBA2 mRNA and is the deletion of two nucleotides (AA) in the polyadenylation signal sequence. This two nucleotide deletion causes the synthesis of an extended HBA2 mRNA transcript that is nonfunctional (PMID: 7947237 (1994)). This pathogenic variant has been observed in either the homozygous or compound heterozygous state in individuals with mild to severe presentations including Hb H disease and a fatal hydrops fetalis (PMID: 16103716 (2005), 17054428 (2006), and 26193977 (2015)).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Quest Diagnostics criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000517.4:c.*93_*94del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14108248</SubmissionName>
          <SubmissionName>SUB8819638</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1167575" SubmissionDate="2024-01-24" DateLastUpdated="2024-02-20" DateCreated="2017-09-30">
        <ClinVarSubmissionID localKey="2218864|MedGen:CN235283" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000603879" DateUpdated="2024-02-20" DateCreated="2017-09-30" Type="SCV" Version="7" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-06-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The HBA2 c.*93_*94del variant (rs63751268, HbVar ID: 1072) has been described in the heterozygous state in individuals affected with microcytic hypochromic anemia (Harteveld 1994, HbVar database and references therein). It has been reported in individuals with Hb H disease in the homozygous state (Deshpande 2015, Farashi 2015, Nair 2013) and in the compound heterozygous state with HBA2 Ala130Pro (Deshpande 2015). Furthermore, the c.*93_*94del variant has been reported in the compound heterozygous state with the 3.7kb deletion (Prior 2007) or additional pathogenic variants (Deshpande 2015) in individuals with hematology compatible with alpha thalassemia trait. The c.*93_*94del variant has also been observed to segregate with disease in families (Deshpande 2015, Farashi 2015, Hartveld 1994, Nair 2013, Prior 2007). This variant is absent from the Genome Aggregation Database, indicating it is not a common polymorphism. This variant deletes two nucleotides in the 3'UTR in the conserved polyadenylation signal and is predicted to result in an elongated transcript. Several other pathogenic variants in the polyadenylation signal have been reported, and homozygosity of pathogenic variants affecting the HBA2 polyadenylation site has been associated with Hb H disease (Higgs 1983, Thein 1988, Whitelaw 1986). Observations of individuals homozygous for either the c.*93_*94del variant or another variant in the HBA2 polyadenylation signal indicate that these variants may interfere with expression of both HBA2 and HBA1 (Harteveld 1994, Higgs 1983, Thein 1988). Based on available information, the c.*93_*94del variant is considered pathogenic. REFERENCES Link to HbVar database: https://globin.bx.psu.edu/hbvar/hbvar.html Deshpande P et al. Characterization of Clinical and Laboratory Profiles of the Deletional a2-Globin Gene Polyadenylation Signal Sequence (AATAAA &gt; AATA- -) in an Indian Population. Hemoglobin. 2015;39(6):415-8. PMID: 26365411. Farashi S et al. Homozygosity for the AATAAA &gt; AATA- - Polyadenylation Site Mutation on the a2-Globin Gene Causing Transfusion-Dependent Hb H Disease in an Iranian Patient: A Case Report. Hemoglobin. 2015;39(5):355-8. PMID: 26193977. Harteveld CL et al. A novel polyadenylation signal mutation in the alpha 2-globin gene causing alpha thalassaemia. Br J Haematol. 1994; 87(1):139-43. PMID: 7947237. Higgs D et al. Alpha-thalassaemia caused by a polyadenylation signal mutation. Nature. 1983; 306(5941):398-400. PMID: 6646217. Nair SB et al. Variable presentation of HB H disease due to homozygosity for the rare polyadenylation signal A T(Indian) (AATAAA&gt;AATA- -) mutation in four Indian families. Hemoglobin. 2013;37(3):277-84. PMID: 23517369. Prior JF et al. A moderately severe alpha-thalassemia condition resulting from a combination of the alpha2 polyadenylation signal (AATAAA--&gt;AATA- -) mutation and a 3.7 Kb alpha gene deletion in an Australian family. Hemoglobin. 2007;31(2):173-7. PMID: 17486499. Thein S et al. The polyadenylation site mutation in the alpha-globin gene cluster. Blood. 1988; 71(2):313-9. PMID: 3337900. Whitelaw E et al. Alpha-thalassaemia caused by a poly(A) site mutation reveals that transcriptional termination is linked to 3' end processing in the human alpha 2 globin gene. EMBO J. 1986; 5(11):2915-22. PMID: 3024968.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process 2024</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/xwiqgyug/arup_molecular_germline_variant_investigation_process_arup-info-0022_2024.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.223692_223693del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN235283" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2020 ARUP</SubmissionName>
          <SubmissionName>2022 ARUP ClinVar submission</SubmissionName>
          <SubmissionName>2023 ARUP ClinVar submission</SubmissionName>
          <SubmissionName>ARUP Molecular 2021</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4081763" TraitType="Disease" MappingType="Name" MappingValue="Alpha thalassemia" MappingRef="Preferred">
        <MedGen CUI="C0002312" Name="alpha Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1167575" TraitType="Disease" MappingType="XRef" MappingValue="CN235283" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2897070" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5002441" TraitType="Disease" MappingType="XRef" MappingValue="604131" MappingRef="OMIM">
        <MedGen CUI="C0002312" Name="alpha Thalassemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

